MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
The Lancet Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

832 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
832 works in the cohort · of 4,299,418page 9 of 17

Labels cover 9 of 832 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 832 of 832 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Paolo A. Ascierto, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl D. Lewis, Светлана Проценко +13 more
2022· article· en· The Lancet Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
104
citations
affno abstractunlabeled
Paediatric extracranial germ-cell tumours
Furqan Shaikh, Matthew J. Murray, James F. Amatruda, Nicholas Coleman, James C. Nicholson, Juliet Hale +8 more
2016· review· en· The Lancet Oncology· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
101
citations
affno abstractunlabeled
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo +19 more
2023· article· en· The Lancet Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrowconsensus · none
101
citations
affno abstractunlabeled
Common Sense Oncology: outcomes that matter
Christopher M. Booth, Manju Sengar, Aaron M. Goodman, Brooke E. Wilson, Ajay Aggarwal, Scott Berry +30 more
2023· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
101
citations
afffundno abstractunlabeled
Rare cancers: a sea of opportunity
Niki Boyd, Janet Dancey, C. Blake Gilks, David G. Huntsman
2016· review· en· The Lancet Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
100
citations
fundno affunlabeled
Chromatin organisation and cancer prognosis: a pan-cancer study
Andreas Kleppe, Fritz Albregtsen, Ljiljana Vlatkovic, Manohar Pradhan, Birgitte Nielsen, Tarjei S. Hveem +10 more
2018· article· en· The Lancet Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
94
citations
aboutno affno abstractunlabeled
Cancer patterns in Inuit populations
Jeppe Friborg, Mads Melbye
2008· review· en· The Lancet Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
92
citations
affno abstractunlabeled
Outcomes and endpoints in cancer trials: bridging the divide
Michelle Wilson, Deborah Collyar, Diana T. Chingos, Michael Friedländer, Tony W. Ho, Katherine Karakasis +5 more
2014· review· en· The Lancet Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
91
citations
affno abstractunlabeled
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial
Tomasz M. Beer, Sebastién J. Hotte, Fred Saad, B. Yа. Alekseev, В. Б. Матвеев, Aude Fléchon +8 more
2017· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
89
citations
affno abstractunlabeled
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
Daniel P. Petrylak, Ronald de Wit, Kim N., Alexandra Drakaki, Cora N. Sternberg, Hiroyuki Nishiyama +138 more
2019· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
85
citations
affno abstractunlabeled
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Marianne Pavel, Simron Singh, Jonathan Strosberg, Lida Bubuteishvili‐Pacaud, Evgeny Degtyarev, Maureen P. Neary +18 more
2017· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
84
citations
affno abstractunlabeled
Global Task Force on Radiotherapy for Cancer Control
David A. Jaffray, Felícia Marie Knaul, Rifat Atun, Cary Adams, Michael Bartoň, Michaël Baumann +8 more
2015· letter· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrityconsensus · none
77
citations
affno abstractunlabeled
Exercise as part of routine cancer care
Daniel Santa Mina, David M. Langelier, Scott C. Adams, Shabbir M.H. Alibhai, Martin Chasen, Kristin L. Campbell +3 more
2018· letter· en· The Lancet Oncology· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
75
citations
affunlabeled
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
David Cameron, James P. Morden, Peter Canney, Galina Velikova, Robert E. Coleman, John M.S. Bartlett +17 more
2017· article· en· The Lancet Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrowconsensus · none
74
citations

How this was built: Screen · Findings · About